What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company reported some positive data for two key programs in development, hepatitis C virus (HCV) sales slid much further than expected.
Gilead Sciences shocked the market in February with a disturbingly bleak sales forecast for its HCV franchise, which peaked at $19.1 billion in 2015. In July, management lifted investors' spirits by nudging the lower end of its 2017 forecast from $7.5 billion to $8.5 billion after total hepatitis C sales ticked a bit higher sequentially in the second quarter.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
71,02 €
0,07 %
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.
